Infliximab for Behçet disease with aortic involvement: two novel case reports without concurrent use of immunosuppressive agents or corticosteroids

Ryo RokutandaDivision of Allergy and Rheumatology, St. Luke’s International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, JapanCorrespondence[email protected]

Masato OkadaDivision of Allergy and Rheumatology, St. Luke’s International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan

Kenichi YamaguchiDivision of Allergy and Rheumatology, St. Luke’s International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan

Taiki NozakiDepartment of Radiology, St. Luke’s International Hospital, Tokyo, Japan

Gautam A. DeshpandeSt. Luke’s Life Science Institute Center for Clinical Epidemiology, Tokyo, Japan

Mitsumasa KishimotoDivision of Allergy and Rheumatology, St. Luke’s International Hospital, 9-1 Akashi-cho, Chuo-ku, Tokyo 104-8560, Japan

REFERENCES

Yazici H. Behçet's syndrome: where do we stand? Am J Med. 2002;112:75-6.
Google Scholar
Lakhanpal S, Tani K, Lie JT, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behget's syndrome: a review of Japanese autopsy registry data. Hum Pathol. 1985;16:790–5.
PubMed Web of Science ®Google Scholar
Saadoun D, Ash B, Wechsler B, Houman H, Geri G, Desseaux K, et al. Long-term outcome of arterial lesions in Behget disease: a series of 101 patients. Medicine. 2012;91:18–24.
PubMed Web of Science ®Google Scholar
Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. Management of Behget disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behget disease. Ann Rheum Dis. 2009;68:1528–34.
PubMed Web of Science ®Google Scholar
Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41:61–70.
PubMed Web of Science ®Google Scholar
Adler S, Baumgartner I, Villiger PM. Behget's disease: successful treatment with infliximab in 7 patients with severe vascular manifestations. A retrospective analysis. Arthritis Care Res. 2012;64(4):607–11.
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Infliximab for Behçet disease with aortic involvement: two novel case reports without concurrent use of immunosuppressive agents or corticosteroids

REFERENCES

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Infliximab for Behçet disease with aortic involvement: two novel case reports without concurrent use of immunosuppressive agents or corticosteroids

REFERENCES

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date